FibroGen Inc (FGEN)
0.396
+0.01
(+2.27%)
USD |
NASDAQ |
Nov 22, 15:25
FibroGen Shareholders Equity (Quarterly): -243.67M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -243.67M |
| June 30, 2024 | -232.34M |
| March 31, 2024 | -228.12M |
| December 31, 2023 | -204.17M |
| September 30, 2023 | -157.17M |
| June 30, 2023 | -102.27M |
| March 31, 2023 | -48.85M |
| December 31, 2022 | -21.45M |
| September 30, 2022 | 26.31M |
| June 30, 2022 | 103.78M |
| March 31, 2022 | 158.05M |
| December 31, 2021 | 209.15M |
| September 30, 2021 | 325.79M |
| June 30, 2021 | 260.58M |
| March 31, 2021 | 371.00M |
| December 31, 2020 | 422.18M |
| September 30, 2020 | 451.66M |
| June 30, 2020 | 395.87M |
| March 31, 2020 | 458.36M |
| December 31, 2019 | 516.14M |
| September 30, 2019 | 594.45M |
| June 30, 2019 | 629.03M |
| Date | Value |
|---|---|
| March 31, 2019 | 489.22M |
| December 31, 2018 | 509.20M |
| September 30, 2018 | 471.31M |
| June 30, 2018 | 495.53M |
| March 31, 2018 | 499.52M |
| December 31, 2017 | 528.47M |
| September 30, 2017 | 571.50M |
| June 30, 2017 | 230.10M |
| March 31, 2017 | 131.70M |
| December 31, 2016 | 155.84M |
| September 30, 2016 | 178.34M |
| June 30, 2016 | 193.11M |
| March 31, 2016 | 156.95M |
| December 31, 2015 | 177.55M |
| September 30, 2015 | 217.28M |
| June 30, 2015 | 253.62M |
| March 31, 2015 | 184.62M |
| December 31, 2014 | 221.40M |
| September 30, 2014 | 81.77M |
| June 30, 2014 | 111.99M |
| December 31, 2013 | 79.73M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-243.67M
Minimum
Sep 2024
516.14M
Maximum
Dec 2019
123.04M
Average
130.91M
Median
Shareholders Equity (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 5.413B |
| Arbutus Biopharma Corp | 106.89M |
| GlycoMimetics Inc | 11.38M |
| Cidara Therapeutics Inc | 115.63M |
| Cue Biopharma Inc | 25.37M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 264.42M |
| Total Liabilities (Quarterly) | 466.12M |
| Debt to Equity Ratio | -0.2987 |
| Current Ratio | 1.283 |
| Net Debt Paydown Yield | -0.68% |